News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx's Traficet-EN™ Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
First-in-class Oral Therapeutic for IBD with Novel Mode of Action
View HTML
Toggle Summary ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
Development Candidate Triggers Milestone Payment from GlaxoSmithKline
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease
Company Also Reports Significant Progress in Advancing Second-Generation CCR9 Drug towards Clinic
View HTML
Toggle Summary ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN™ ) in Crohn's Disease
Company Also Reports Significant Progress in Advancing Second-Generation CCR9 Drug towards Clinic
View HTML
Toggle Summary ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
Milestone Triggers $10 Million Payment from Partner GlaxoSmithKline
View HTML
Toggle Summary ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors Mountain View, CA - January 17, 2008 - ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and
View HTML
Toggle Summary ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Characterization of Receptor's Central Role in Cancer is Published in the Proceedings of the National Academy of Sciences
View HTML
Toggle Summary ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered
View HTML